J&J suing Samsung Bioepis over Stelara biosimilar

J&J sues Samsung Bioepis over Stelara biosimilar
Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis treatment.
J&J Takes Samsung Bioepis to Court Over ‘Unlawful’ Stelara Biosimilar Sublicense
Samsung Bioepis allegedly entered into an agreement with a third-party health company, allowing it to market its own private label of a Stelara biosimilar.
Biosimilar Battle: J&J Sues Samsung Over Stelara Market Intrusion
Johnson & Johnson filed a lawsuit against Samsung Bioepis for allegedly breaching their agreement over the launch of Stelara's biosimilar, Pyzchiva. J&J seeks to prevent its U.S. sales, claiming unauthorized sublicense dealing damaged J&J's market share.
J&J seeks to stop Sam­sung Bioepis from li­cens­ing Ste­lara biosim­i­lar
Johnson & Johnson is suing Samsung Bioepis for allegedly breaching the terms of a contract regarding the launch of the Korean biotech’s Stelara biosimilar.
J&J sues Samsung Bioepis over ‘surreptitious’ breach of Stelara biosimilar contract
Samsung Bioepis has allegedly sub-licensed its Stelara biosimilar rights to a health conglomerate, breaching a previous settlement.
J&J sues Samsung Bioepis over contract breach for Stelara biosimilar
Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the drugmaker over the launch of a biosimilar to Stelara, J&J's autoimmune drug.
J&J sues Samsung over a contract breach for a Stelara biosimilar
As biosimilar versions of a big-selling Johnson & Johnson medicine reach the U.S. market, the health care giant accused one manufacturer of striking a
Samsung Bioepis Announces US Launch of PYZCHIVA(R) (ustekinumab-ttwe), Biosimilar to Stelara
Samsung Bioepis Co., Ltd. today announced that PYZCHIVA(R) (ustekinumab-ttwe), a biosimilar to Stelara (ustekinumab), is now available in the United States. PYZCHIVA has been appr
centerforbiosimilars18h
3 Ustekinumab Biosimilars Launch on US Market
Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...
Managed Healthcare Executive4d
Second Biosimilar of Stelara Launches
Teva and Alvotech are introducing Selarsdi at an 85% discount off the reference product Stelara. Selarsdi is available as a subcutaneous injection and for intravenous infusion.